Elite Pharmaceuticals Files ANDA for Generic Anticoagulant on June 1, 2026

Elite Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic anticoagulant product. The application seeks approval to manufacture and market a generic version of an established anticoagulant medication.

The company announced the filing on Monday, June 1, 2026. The ANDA contains data that demonstrates that the proposed generic drug is bioequivalent to the reference listed drug. If approved, Elite Pharmaceuticals will be able to manufacture and commercialize this generic anticoagulant, expanding its portfolio of pharmaceutical products.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI